7,651.50

+37.50

+0.49%

52,201.00

+283.00

+0.55%

28,758.50

+224.50

+0.79%

Russell 2000 Futures

2,843.00

+21.70

+0.77%

4.9290

-0.0600

-1.20%

18.91

-0.51

-2.63%

3,907.10

+8.20

+0.21%

77,904.92

+16.82

+0.02%

Crude Oil Dec 26

99.97

-4.15

-3.99%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Curis, Inc. (CRIS)

0.6000 +0.0515 (+9.39%)

At close: October 30 at 4:00:01 PM EDT

0.6100 +0.0100 (+1.67%)

Pre-Market: 5:31:43 AM EST

Loading Chart for CRIS

Chart Range Bar

Interval:

In partnership with ChartIQ

Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors

Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors

VISTA Inhibitor Market Insights Report 2026 | Featuring Profiles of Aurigene Discovery Technologies, Curis, Hummingbird Bioscience, Kineta, PharmAbcine

VISTA Inhibitor Market Insights Report 2026 | Featuring Profiles of Aurigene Discovery Technologies, Curis, Hummingbird Bioscience, Kineta, PharmAbcine

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework

Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework

Curis Doses First Five Patients in TakeAim CLL Study

Curis Doses First Five Patients in TakeAim CLL Study

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus

Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus

Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)

Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)

Curis Announces Positive Emavusertib Update

Curis Announces Positive Emavusertib Update

Curis opens 11 sites for emavusertib combo in TakeAim CLL trial

Curis opens 11 sites for emavusertib combo in TakeAim CLL trial

Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk

Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk

Mobilize your Website

View Site in Mobile | Classic

Share by: